Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)

Condition(s) targeted: Preterm Premature Rupture of Membranes

Intervention: indomethacin (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Thomas Jefferson University

Official(s) and/or principal investigator(s):
Jolene S Seibel-Seamon, MD, Principal Investigator, Affiliation: Thomas Jefferson University

Overall contact:
Jolene S Seibel-Seamon, MD, Phone: 215-955-9239, Email: joleneseibel@yahoo.com

The purpose of this study is to determine if the short term use of indomethacin will reduce the number of women delivering within 48 hours when given to women with preterm premature rupture of membranes (PPROM) between 24- 32 weeks of gestation. We hypothesize that indomethacin's anti-inflammatory and tocolytic action will reduce the number of women delivering within 48 hours when given to women with PPROM between 24-32 weeks of gestation.

Official title: A Double-Blinded Randomized Controlled Trial With Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Between 24 and 32 Weeks Gestation

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome: Prolongation of pregnancy (interval from time of randomization to time of delivery) for 48 hours

Secondary outcome:

Prolongation of pregnancy for 7 days

Neonatal Morbidities: birth weight, APGAR scores, sepsis, respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), NICU hospitalization days, patent ductus arteriosus (PDA)

Maternal outcomes: chorioamnionitis, endometritis, labor induction, placental abruption, cesarean section

Detailed description: Preterm premature rupture of membranes (PPROM) is defined as rupture of the chorioamniotic membranes before the onset of labor prior to 37 weeks of gestation. The etiology of PPROM is not well understood but likely to be multifactorial. Although the underlying mechanism of PPROM is unknown, some speculate it is the human's inflammatory response to bacterial infection with the subsequent production of prostaglandins which weaken the fetal membranes. Therefore, the use of indomethacin, a prostaglandin inhibitor, may decrease prostaglandin synthesis leading to less uterine irritability and prevention of weakened membranes.

This is a double blind randomized controlled trial comparing indomethacin to placebo in women with PPROM between the gestational ages of 24-32 weeks. Women between the gestational age of 24 to 32 weeks with premature rupture of membranes and not in active labor will be eligible for this clinical trial. After informed consent, patients will be randomized to either indomethacin or placebo. Maternal and neonatal outcomes will be assessed.

Minimum age: 15 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Gestational age between 24 0/7 - 31 5/7 weeks by LMP or ultrasound

- Documentation of rupture by demonstrating pooling or 2/3 diagnostic tests (pooling,

ferning and nitrazine positivity)

Exclusion Criteria:

- Membrane rupture greater than 72 hours

- Persistent labor characterized by regular painful contractions with cervical change

and/or cervix visually greater than 5 cm

- Chorioamnionitis defined by having 2 or more of the following: maternal temperature >

100. 4, persistent fetal tachycardia (>170bpm), maternal tachycardia (>110bpm) in the absence of other likely cause, uterine tenderness.

- Non-reassuring fetal heart rate tracing or biophysical testing

- Vaginal hemorrhage

- Lethal fetal anomalies

- Intrauterine fetal demise

- Maternal conditions which precludes expectant management

- Fetal condition which precludes expectant management

- Maternal allergy to indomethacin

- Maternal active gastritis

- Multiple gestations

- HIV with viral load >1000

- HSV with active herpetic lesions

- Cervical cerclage

Jolene S Seibel-Seamon, MD, Phone: 215-955-9239, Email: joleneseibel@yahoo.com

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107, United States; Recruiting
Jolene S Seibel-Seamon, MD, Phone: 215-955-6293, Email: joleneseibel@yahoo.com
Jolene S Seibel-Seamon, MD, Principal Investigator

Starting date: April 2007
Ending date: April 2010
Last updated: May 29, 2008